New pill tested for rare, spreading eye cancer
NCT ID NCT07136181
Summary
This study is testing a new oral drug called NBM-BMX for people with metastatic uveal melanoma, a rare type of eye cancer that has spread. The main goals are to find a safe and effective dose, learn about side effects, and see if the drug can shrink or slow the growth of tumors. Participants will take capsules twice daily and continue treatment as long as it is helping and side effects are manageable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Honor Health Resarch Institute
RECRUITINGScottsdale, Arizona, 85258, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute (SCRI) - Denver HealthONE Location
RECRUITINGDenver, Colorado, 80218, United States
Conditions
Explore the condition pages connected to this study.